BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc., a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, ...

Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation with clinically and commercially validated platform capabilities Cash runway maintained into 1H ...

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported ...

Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, ...

EST Pyxis Oncology (PYXS) files $350M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving ...

Guggenheim 2 nd Annual Healthcare Innovation Conference, Boston, MA, Monday, November 10, 2:30 p.m. ET. – Fireside chat. Stifel 2025 Healthcare Conference, New York ...

BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that it ...

On Wednesday, Pyxis Oncology, Inc. (NASDAQ:PYXS) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. Among evaluable Head and ...

LEXINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alloy Therapeutics (“Alloy”) and Pyxis Oncology ("Pyxis") today announced the formation of a joint venture named Kyma Therapeutics to develop ...

Pyxis Oncology, Inc. announced that its Compensation Committee has granted stock options for a total of 246,238 shares of its common stock to four newly hired employees, under the 2022 Inducement Plan ...

BOSTON--(BUSINESS WIRE)--Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor ...